A Phase I Dose-Escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma.

Trial Profile

A Phase I Dose-Escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs OSI 027 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 22 Mar 2016 Results published in the British Journal of Cancer
    • 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2012 Planned number of patients changed from 130 to 160 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top